Aptar receives CE marking for intranasal vaccine delivery devices
What happened
Aptar Pharma, part of AptarGroup, Inc., received CE marking for its LuerVax intranasal delivery device and accompanying Spray Divider. This approval was granted under the EU Medical Device Regulation (MDR), confirming the devices meet European general safety and performance requirements. The devices are designed to support the development of intranasal vaccine products from early clinical studies through commercialization.
From finanznachrichten.de
Why it matters
The CE marking provides a compliant delivery platform for vaccine developers, strengthening Aptar Pharma's ability to support customers in the European market. This milestone expands the scope of Aptar Pharma's offerings for innovative intranasal vaccine products.
From finanznachrichten.de
Who's involved
- AptarGlobal leader in drug delivery, dosing, and protection technologies
- Vladimir PutinFormer President and Prime Minister of Russia
- Australian Research CouncilAustralian Government's main research funding body for tertiary institutions
- BerazateguiCity in Buenos Aires Province, Argentina where Aptar established a facility
- ArgentinaCountry where Aptar is expanding local manufacturing operations
Keep exploring
The entities involved
-
Aptar
company in Crystal Lake, United States
Nothing else this week.